Media room

Editorial work about the manufacturer's continuing memory

Medicines Systems Quarterly

Fictional professional journal; illustrative placement

A restoration result needs an account of what can be understood

I describe the difference between a completed backup job and a restored package that can be interpreted for its intended review. The article follows fourteen fictional exercises, three missing method-context results and the funded work that followed. It explains why the original sources remained available and why the technical report did not claim universal readiness or borrow the quality function's authority to assess suitability.

The Record Continuity Review

Invented editorial publication; demonstration entry

Reasons for changes cannot be invented at rollout

I examine an electronic batch-record rehearsal that preserved change history but failed to capture adequate reasons in six of thirty records. The account includes an eight-week hold, EUR620,000 continuation cost and the distinct responsibilities of technology and quality colleagues. I explain why a tidier retrospective explanation would not resolve the original capture weakness, and how a corrected rehearsal remained evidence with a defined scope.

Laboratory Stewardship Notes

Fictional specialist newsletter; illustrative entry

The sample that kept a reader in service

I discuss the 144 historical packages that still required an older reader within a 1,200-package sample. The piece distinguishes a controlled retrieval obligation from continuing all the old application's activities. It also explains why the selected sample did not support extrapolation to the entire archive, and why an anticipated annual saving needed a separate account from the defined cost of retaining the capability.

Manufacturing Evidence Letters

Invented manufacturing management periodical; no real publication claim

Eighteen failed scenarios and a different release date

I set out how a manufacturer can examine a supplier release without allowing the supplier timetable to become its acceptance standard. The fictional case separates eleven display-mapping discrepancies from seven permission-boundary failures and keeps the EUR780,000 support cost visible. I describe the scope of controlled tests, the treatment of corrected evidence and the responsibilities that remain with operating and quality colleagues after a technical recommendation.

Regulated Technology Decisions

Fictional executive publication; demonstration only

Funding does not create experienced reviewers on demand

I explore a deferred analytics proposal whose missing resource was specialist participation rather than development funding alone. The article explains the EUR24 million approved change allocation, a separate EUR4.2 million request and the narrower option that still depended on the same reviewers. I argue for an explicit capacity requirement and a route to reconsideration, preserving the opportunity cost of delay without calling unapproved expenditure a saving.

Media biography

Stefan Duvall is a fictional European chief information officer whose career concerns the continuity of manufacturing and laboratory records through technological change. He leads technology at the illustrative Orvanel Therapeutics, a Lyon-headquartered established-medicines manufacturer with 4,600 employees and EUR1.36 billion revenue in 2025. His own remit comprises 144 employees, six direct reports and EUR68 million technology authority for 2026; forty-two contractors are counted separately.

Duvall began in systems analysis at Cerlun Pharmaceuticals in September 1994 and joined Orvanel in April 2002. Appointments in plant informatics, laboratory systems and enterprise systems preceded his January 2020 promotion to CIO. His writing addresses usable record context, supplier-release evidence, archive dependencies and specialist review capacity. He presents to directors but has no board seat. The companies, colleagues, publication entries and decisions shown here are invented for this leadership-website demonstration. They are not clinical advice, regulatory endorsements or evidence of actual product outcomes. His proposed external governance availability is twenty-one days annually, subject to consent and appointment-specific assessment.

Biographies

Approved text

Short speaker biography

I am Stefan Duvall, a fictional European pharmaceutical CIO with thirty-two years in manufacturing and laboratory technology. I speak about preserving record meaning through change, examining supplier releases and recognising the specialist capacity behind an investment plan. My examples distinguish technical evidence from the quality and operating decisions it supports.

Standard speaker biography

I lead technology at the fictional Orvanel Therapeutics, with 144 employees and EUR68 million of authority for 2026. My career began in manufacturing systems analysis in 1994 and developed through plant informatics, laboratory applications and enterprise systems. I discuss the practical obligations that remain after a technical milestone: interpreting earlier records, supporting an older reader and obtaining the experienced review needed for change. My sessions use clearly invented cases with stated costs and limitations. I present to directors as an executive but hold no board seat. I aim to give sponsors and directors better questions about the evidence behind a technology recommendation, without substituting for quality judgement or specialist legal advice.

Extended speaker biography

I am the fictional CIO of Orvanel Therapeutics, a Lyon-headquartered manufacturer of established prescription medicines with operations in France, Belgium and the Netherlands. I lead 144 technology employees through six direct reports, supported by forty-two contractors counted separately. My 2026 authority is EUR68 million, divided between EUR44 million continuing operations and EUR24 million change. I report to the CEO and present technology matters to directors; I have not served as a director myself.

My career started at Cerlun Pharmaceuticals in September 1994, after an information systems master's degree. I joined Orvanel in plant informatics in 2002, moved into laboratory systems in 2009 and enterprise systems in 2014, and became CIO in January 2020. Those roles shaped my interest in the meaning that must survive a change of application, instrument or supplier.

In executive sessions I discuss restoration exercises, release acceptance, archive retrieval and the finite review capacity behind investment schedules. My cases retain their costs and qualifications: a successful test has a scope, an old reader can remain necessary and a deferred request is not automatically a saving. I do not provide clinical recommendations or represent technical completion as regulatory endorsement. I want participants to examine the account they would need before making their own next decision.

An invitation

Contact

I am open to a carefully scoped non-executive conversation where technology, manufacturing and evidence stewardship meet. An external role would need employer agreement, a workable twenty-one-day annual commitment and a proper examination of conflicts and appointment requirements.

Open to

Board appointments
Speaking invitations
Executive opportunities

Write to Stefan

office@stefanduvall.example